Polen Capital, an investment management company, released its fourth-quarter investor letter for “Polen 5Perspectives Small Growth Strategy”. A copy of the letter can be downloaded here. The Polen 5Perspectives Small Growth Composite Portfolio returned -1.3% gross and -1.5% net of fees in the fourth quarter of 2025, compared to a 1.2% return of the Russell 2000 Growth Index. Following double-digit returns in 2Q and 3Q, small caps concluded the year with a 1.2% return in 4Q. Biotech stood out as a major performer during the quarter, expanding beyond the AI theme. The small-cap asset class has gained attention due to declining interest rates and improving earnings growth, but the firm is most excited about its structural tailwinds, including the rapid pace of innovation and the opportunity it presents for disciplined investors. Over the fourth quarter, the Strategy nearly doubled its Biotech exposure due to opportunities presented by rising interest rates, M&A, and AI tailwinds. The name of the Strategy changed from Polen U.S. Small Cap Growth to Polen 5Perspectives Small Growth, to emphasize the significance of the 5 viewpoints framework and the influence of perspective in investing. In addition, please check the Strategy’s top five holdings to know its best picks in 2025.
In its fourth-quarter 2025 investor letter, Polen 5Perspectives Small Growth Strategy highlighted Corcept Therapeutics Incorporated (NASDAQ:CORT). Corcept Therapeutics Incorporated (NASDAQ:CORT) is pharmaceutical company focuses on the development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders. On February 23, 2026, Corcept Therapeutics Incorporated (NASDAQ:CORT) stock closed at $35.34 per share. One-month return of Corcept Therapeutics Incorporated (NASDAQ:CORT) was -22.56%, and its shares lost 42.82% over the past 52 weeks. Corcept Therapeutics Incorporated (NASDAQ:CORT) has a market capitalization of $3.724 billion.
Polen 5Perspectives Small Growth Strategy stated the following regarding Corcept Therapeutics Incorporated (NASDAQ:CORT) in its fourth quarter 2025 investor letter:
“Corcept Therapeutics Incorporated (NASDAQ:CORT) is a biopharmaceutical company focused on developing drugs that modulate cortisol activity, with its flagship product Korlym approved for Cushing’s syndrome and a growing pipeline in oncology and metabolic disorders. We feel Corcept is at an inflection point as it expands beyond its core indication, driven by promising Phase 3 data for relacorilant in adrenal cancer and other indications. However, during the quarter, the stock was pressured due to concerns about slower Korlym sales growth and uncertainty around timing of pipeline approvals.”
